Live Breaking News & Updates on Washington University School Of Medicine In St Louis

Stay updated with breaking news from Washington university school of medicine in st louis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investigation of Novel Management Strategies Continues to Mitigate Disease-Related Toxicities Across Hematologic Malignancies

Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis. ....

United States , Washington University , Elaine Majerus , Peter Riedell , Kristen Sanfilippo , Amyw Zhou , Washington University School Of Medicine , Department Of Medicine , University Of Chicago , Division Of Hematology , Science Summit , Washington University School , Sana Saif Ur Rehman , Jak Inhibitors In Myelofibrosis , The University Of Chicago , Stephen Oh , Washington University School Of Medicine In St Louis ,

Dr Van Tine on the SPEARHEAD-1 Trial of Afami-Cel in Advanced Synovial Sarcoma

Brian A. Van Tine, MD, PhD, discusses findings from the overall survival analysis of the phase 2 SPEARHEAD-1 trial in patients with advanced synovial sarcoma. ....

Briana Van , Department Of Pediatrics , Department Of Medicine , Division Of Oncology , Washington University School Of Medicine , Medical Oncology , Washington University School , Van Tine , Briana Van Tine , Spearhead 1 Trial , Patients With Advanced Synovial Sarcoma , Washington University School Of Medicine In St Louis ,

Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma

Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.
....

Briana Van , Division Of Oncology , Washington University School Of Medicine , Siteman Cancer Center , Medical Oncology , Washington University School , Van Tine , Washington University School Of Medicine In St Louis , Onclive Tv ,

Dr Bagegni on the Prevalence of ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

Nusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan. ....

Nusayba Bagegni , Washington University School Of Medicine , Siteman Cancer Center , Division Of Medical Oncology , Medical Oncology , Washington University School , Washington University School Of Medicine In St Louis , Neoadjuvant Her2 , Onclive Tv , Interstitial Lung Disease , Her2 Positive Breast Cancer , Am Trastuzumab Deruxtecan Nxki Enhertu , Trastuzumab Deruxtecan ,

Jumping Genes in Cancer Cells Open Door to New Immunotherapies

Research from Washington University School of Medicine in St. Louis suggests that transposable elements in various cancers potentially may be used to direct novel immunotherapies to tumors that don’t typically respond to immune-based treatments. ....

Karenp Loewentheil , Cancer Genome Atlas Program , National Cancer Institute , Siteman Cancer Center , Washington University School Of Medicine , Washington University School , Ting Wang , Distinguished Professor , Barnes Jewish Hospital , Washington University School Of Medicine In St Louis ,